Several studies have shown that IL-33, via its receptor ST2, activates various signalling pathways, including those of PI3K/AKT, MAPKs, NF-κB, JNK-cJun, and ERK1/2, to promote cancer progression15,28,29,46,53. This evidence concerns the gene JUN and cancer.